The incidence and clinical correlates of lithium toxicity: a retrospective review

被引:18
作者
Dennison, U. [1 ,2 ,3 ]
Clarkson, M. [1 ,2 ,3 ]
O'Mullane, J. [1 ,2 ,3 ]
Cassidy, E. M. [1 ,2 ,3 ]
机构
[1] Cork Univ Hosp, Dept Psychiat, Cork, Ireland
[2] Cork Univ Hosp, Dept Renal Med, Cork, Ireland
[3] Cork Univ Hosp, Dept Pathol, Cork, Ireland
关键词
Lithium toxicity; Clinical correlates; Neurological symptoms; Outcomes; BIPOLAR DISORDER; RISK; INTOXICATION; METAANALYSIS; PROPHYLAXIS; GUIDELINES; MORBIDITY;
D O I
10.1007/s11845-011-0712-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Lithium is a commonly prescribed pharmacological treatment for mood disorders. It is associated with a number of side effects and potentially serious toxicity. To date, there is little data from Irish samples on the subject of Lithium toxicity. To examine the incidence and clinical correlates of lithium toxicity in Cork, Ireland. Our study identified 130 cases of biochemical lithium toxicity over 5 years, with an incidence rate of approximately 5.4 cases per 100,000 per year. Mean toxic lithium level was 2.16 mmol/L +/- SD 0.87 mmol/L. Of these, 36% cases were reviewed medically in the general hospital at the time of toxicity. A number of issues in relation to lithium toxicity were identified. Neurological symptoms were common, including tremor, confusion, ataxia, drowsiness. However, only 4.2% patients were reviewed by a neurologist while in hospital. Medications that interact with lithium were found in 50% cases, with significant polypharmacy in 15%. The psychiatric services were involved in patient care in 76% cases, and 85% patients presenting with toxicity were reviewed by a psychiatrist. Rates of admission to hospital and haemodialysis were 70 and 11%, respectively. Improvements in the standards of care in relation to lithium prescribing are required.
引用
收藏
页码:661 / 665
页数:5
相关论文
共 26 条
[1]   Lithium toxicity: A double-edged sword [J].
Alexander, M. P. ;
Farag, Y. M. K. ;
Mittal, B. V. ;
Rennke, H. G. ;
Singh, A. K. .
KIDNEY INTERNATIONAL, 2008, 73 (02) :233-237
[2]   SERUM LEVEL MONITORING AND CLINICAL PHARMACOKINETICS OF LITHIUM [J].
AMDISEN, A .
CLINICAL PHARMACOKINETICS, 1977, 2 (02) :73-92
[3]   PERMANENT NEUROLOGICAL DEFICITS DUE TO LITHIUM TOXICITY [J].
APTE, SN ;
LANGSTON, JW .
ANNALS OF NEUROLOGY, 1983, 13 (04) :453-455
[4]   Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review [J].
Baldessarini, Ross J. ;
Tondo, Leonardo ;
Davis, Paula ;
Pompili, Maurizio ;
Goodwin, Frederick K. ;
Hennen, John .
BIPOLAR DISORDERS, 2006, 8 (05) :625-639
[5]   Lithium augmentation in treatment-resistant-depression:: Meta-analysis of placebo-controlled studies [J].
Bauer, M ;
Döpfmer, S .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (05) :427-434
[6]  
BIRCH NJ, 1993, LITHIUM, V4, P225
[7]   Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: A systematic review of randomized trials [J].
Cipriani, A ;
Pretty, H ;
Hawton, K ;
Geddes, JR .
AMERICAN JOURNAL OF PSYCHIATRY, 2005, 162 (10) :1805-1819
[8]   DECREASING LITHIUM DOSAGE REDUCES MORBIDITY AND SIDE-EFFECTS DURING PROPHYLAXIS [J].
COPPEN, A ;
ABOUSALEH, M ;
MILLN, P ;
BAILEY, J ;
WOOD, K .
JOURNAL OF AFFECTIVE DISORDERS, 1983, 5 (04) :353-362
[9]   Lithium monitoring before and after the distribution of clinical practice guidelines [J].
Eagles, JM ;
McCann, I ;
MacLeod, TNN ;
Paterson, N .
ACTA PSYCHIATRICA SCANDINAVICA, 2000, 101 (05) :349-353
[10]   Lithium and angiotensin-converting enzyme inhibitors: Evaluation of a potential interaction [J].
Finley, PR ;
OBrien, JG ;
Coleman, RW .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (01) :68-71